Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study

Publication Details

Amyloid

July 2026

Access Here

Author(s)

Marcus A Urey¹, Quan M Bui¹, Laura Obici², Jonas Wixner³, Erwan Donal⁴, Hiroaki Kitaoka⁵, Ainara Lozano-Bahamonde^{6 7}, Shaun Bender⁸, Katherine L Boyle⁸, Emre Aldinc⁸, Caroline Morbach⁹

Affiliations

¹Division of Cardiovascular Medicine, University of California San Diego Health, La Jolla, CA, USA; ²Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; ³Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ⁴CHU Rennes, Inserm, LTSI-UMR 1099, University of Rennes, Rennes, France; ⁵Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, Japan; ⁶Biobizkaia Health Research Institute, Bizkaia, Spain; ⁷Osakidetza Basque Health Service, Basurto University Hospital, Bizkaia, Spain; ⁸Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁹Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, and Department of Medicine I, University Hospital Würzburg, Würzburg, Germany

Abstract

Background:

Patients with transthyretin amyloidosis (ATTR) with cardiomyopathy (CM) can experience extracardiac manifestations, including gastrointestinal (GI) manifestations that negatively impact their quality of life.

Methods:

In the double-blind HELIOS-B study, patients received vutrisiran 25 mg or placebo every 12 weeks for up to 36 months. Reported adverse events classified using preferred terms of the MedDRA GI disorders system organ class were compared between treatment arms in the overall population, the monotherapy population (not receiving tafamidis at baseline) and the baseline tafamidis subgroup.

Results:

Overall, 271/654 patients experienced 529 GI events, 195 in the vutrisiran arm (23.4 events per 100 patient-years) and 334 in the placebo arm (40.6 events/100 patient-years; rate ratio, 0.58; p < 0.0001). With vutrisiran, lower rates were observed for almost all GI events including constipation, diarrhea, nausea, abdominal pain and vomiting, versus placebo, with rates of overall GI events reduced by 38–49% across populations (all p < 0.0001). Reductions in mean cumulative GI events with vutrisiran versus placebo were observed from Month 3.

Conclusions:

Treatment with vutrisiran was associated with substantially fewer GI events versus placebo in patients with ATTR-CM, with the difference beginning early in treatment. Future trials should consider assessment of extracardiac manifestations.